KTTA logo

Pasithea Therapeutics Corp.

KTTA
Healthcare|Biotechnology|US
$0.58
+0.06 (+11.31%)
DCF Value
$7.85
Tangible Book / Share
$6.60
Cash / Share
$6.49

About

Pasithea Therapeutics Corp. functions as a biotechnology firm dedicated to the discovery and advancement of novel therapeutic solutions for various psychiatric and neurological conditions. Beyond its research endeavors, the company also plans to establish and manage clinics specializing in depression treatment. These facilities are designed to offer business support, employing trained pharmacists to administer intravenous ketamine infusions. Founded in 2020, the corporation's primary operations are based in Miami Beach, Florida.

Stock Price

-19.9%(1Y)
1M
+31.3%
3M
+14.2%
6M
-27.2%
YTD
-55.1%
1Y
-20.8%
3Y
-92.3%
5Y
-98.9%

Pipeline Summary

2 total trials
2
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
Recruiting: 2

Active Trials (2)

PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas
NCT06961565NF1 Mutation
Phase 1Recruiting
Enrollment: 56 participants
PAS-004 in Patients With Advanced Solid Tumors
NCT06299839RAS Mutation
Phase 1Recruiting
Enrollment: 83 participants

Key Facts

Market Cap$19.3M
Employees5 (-38% YoY)
CEOTiago Reis Marques
IPO DateSep 15, 2021
Beta0.29
52-Week Range$0.281 – $2.06
Avg Volume528,632
ExchangeNASDAQ
Websitepasithea.com

Ownership

Float96.4%
Shares Outstanding33.4M

Recent Insider Trades

Coastlands Capital LPBUY
Jun 17, 2026100,000 shares @ $0.53
Marques TiagoAWARD
May 1, 20261,756,069 shares @ $0.84
STEINMAN LAWRENCEAWARD
May 1, 2026152,783 shares @ $0.84
Dumesnil SimonAWARD
May 1, 2026152,783 shares @ $0.84
Schneiderman Daniel HAWARD
May 1, 20261,129,323 shares @ $0.84

Peers

AIMAIM ImmunoTech Inc.
$6.2M
CYCNCyclerion Therapeutics, Inc.
$15.7M
IBOImpact BioMedical Inc.
$35.5M
KALAKALA BIO, Inc.
$3.0M
NBYNovaBay Pharmaceuticals, Inc.
$39.1M
PLRZPolyrizon Ltd.
$12.4M
QNRXQuoin Pharmaceuticals, Ltd.
$7.3M
TCRTAlaunos Therapeutics, Inc.
$6.0M

Recent News

Pasithea Therapeutics Announces FDA Clearance of IND for PAS-004 in Neurofibromatosis Type 1 (NF1)-Associated Cutaneous Neurofibromas (cNF)
Nov 3, 2026 · globenewswire.com
Pasithea Therapeutics to Host Virtual KOL Event on NF1 Treatment November 4, 2026
Oct 28, 2026 · globenewswire.com
Pasithea Therapeutics Announces Positive PAS-004 Clinical Data from Phase 1 Advanced Cancer Study Presented at ESMO Congress 2026
Oct 23, 2026 · globenewswire.com
Pasithea Therapeutics (NASDAQ:KTTA) Shares Down 2.7% – Time to Sell?
Oct 4, 2026 · defenseworld.net
Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference
Sep 14, 2026 · globenewswire.com
Data last updated: Nov 9, 2026, 04:18 AM